Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Bayer (XTRA:BAYN) Nears $7.25 Billion Roundup Hearing As FDA Clears New Lung Cancer Drug

13 September 2026 · By · Wire by Fusion42

Published

13 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at simplywall.st →

◆ Verified

Fusion42 · 13 September 2026 · Fusion42 review

Bayer is approaching a $7.25 billion settlement hearing to resolve US cancer lawsuits linked to its Roundup herbicide, while the FDA has granted accelerated approval to Bayer's new lung cancer drug HYRNUO for HER2-mutated non-small cell lung cancer.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your cancer drug pipeline now competes with Bayer's newly FDA-cleared HYRNUO, raising the stakes in HER2 lung cancer treatments. At the same time, the Roundup settlement clears a legal obstacle that may stabilise Bayer's cash flow and reduce litigation risk in the US market.

◆ Coverage

1 source · 13 Sep 2026

◆ Related on Wire

◆ Topics

Biotechbayerroundup-settlementlung-cancer-drugFDA-approvallitigation-risk